- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02430376
dbGaP Protocol: Genetic Variants Associated With Pentalogy of Cantrell
Background:
Pentalogy of Cantrell (POC) is a syndrome that involves many heart abnormalities as well as large defects in the chest and abdominal wall. This often results in the heart and other organs being present outside the body at birth. Surgeons have learned to replace them and repair the heart. Researchers want to find possible gene changes that cause POC. To do this, they want to study data from the Pediatric Cardiovascular Genetics Consortium (PCGC) Cohort. The PCGC collects data and DNA samples from people with heart diseases and their families
Objectives:
- To find gene mutations in people with Pentalogy of Cantrell (POC) or other related syndromes.
Eligibility:
- PCGC data and DNA samples that are open to study by the public.
Design:
- Researchers will study the data from the PCGC.
- The gene testing being done in this study was consented to in the original studies. No new consent or waiver request is required.
- The study will last 1 year.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- We will analyze data from subjects from congenital cardiovascular disease databases.
Study Plan
How is the study designed?
Design Details
- Observational Models: Family-Based
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To identify novel genetic mutations associated with the disease Pentalogy of Cantrell
Time Frame: Ongoing
|
Ongoing
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To identify the molecular mechanisms underlying the congenital disease Pentalogy of Cantrell, to aid in the development of novel therapeutic strategies.
Time Frame: Ongoing
|
Ongoing
|
Collaborators and Investigators
Investigators
- Principal Investigator: Robert S Adelstein, M.D., National Heart, Lung, and Blood Institute (NHLBI)
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 999915111
- 15-H-N111
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pentalogy of Cantrell
-
National Heart, Lung, and Blood Institute (NHLBI)Completed
-
Children's Healthcare of AtlantaEmory University; Brigham and Women's Hospital; University of California, San... and other collaboratorsWithdrawnPentalogy of Cantrell | Mutations in Non-muscle GenesUnited States
-
Jazz PharmaceuticalsCompletedEvaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4 | Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4 | Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19...United Kingdom
-
Chulalongkorn UniversityHIV-NAT, Thai Red Cross - AIDS Research Centre; Chula Clinical Research Center...RecruitingSafety of a Single Dose of COMVIGEN Vaccine | Reactogenicity of a Single Dose of COMVIGEN Vaccine | Immunogenicity of a Single Dose of COMVIGEN Vaccine | Safety of a Single Dose of BIVALENT Pfizer/BNT Vaccine | Reactogenicity of a Single Dose of BIVALENT Pfizer/BNT Vaccine | Immunogenicity...Thailand
-
Chulalongkorn UniversityBioNet-Asia; Chula Clinical Research Center (Chula CRC), Faculty of Medicine... and other collaboratorsRecruitingSafety of 25 ug of ChulaCov19-BNA159 mRNA Vaccine | Tolerability of 25 ug of ChulaCov19-BNA159 mRNA Vaccine | Immune Response of 25 ug of ChulaCov19-BNA159 mRNA Vaccine | Safety of 50 ug of ChulaCov19-BNA159 mRNA Vaccine | Tolerability of 50 ug of ChulaCov19-BNA159 mRNA Vaccine | Immune Response... and other conditionsThailand
-
Methodist University, North CarolinaCompletedAccuracy of Estimation of Joint Range of MotionUnited States
-
Universitätsklinikum Hamburg-EppendorfUniversity of Kiel; University of Valencia; University of Witten/Herdecke; Szeged... and other collaboratorsCompletedReduction of Length of Hospitality Stay, Reduction of Perioperative ComplicationsGermany
-
Matias VestedCompletedOnset Time of Mivacurium, Duration of Action of MivacuriumDenmark
-
Drägerwerk AG & Co. KGaACompletedMonitoring of Regional Distribution of Ventilation | Monitoring of Lung VolumeGermany
-
McGill University Health Centre/Research Institute...CompletedMalunion of Fracture of Clavicle | Delayed Union of Fracture of ClavicleCanada